UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Neurology, 2011-05, Vol.76 (22), p.1858-1865

2011

Volltextzugriff (PDF)

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Multiple sclerosis, 2012-08, Vol.18 (8), p.1074-1080

2012

Volltextzugriff (PDF)

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

Multiple sclerosis, 2008-08, Vol.14 (7), p.940-946

2008

Volltextzugriff (PDF)

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Multiple sclerosis, 1999-08, Vol.5 (4), p.244-250

1999

Volltextzugriff (PDF)

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Multiple sclerosis, 2010-11, Vol.16 (11), p.1385-1392

2010

Volltextzugriff (PDF)

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Neurology, 2001-10, Vol.57 (7), p.1239-1247

2001

Volltextzugriff (PDF)

Eight-year follow-up study of brain atrophy in patients with MS

Neurology, 2002-11, Vol.59 (9), p.1412-1420

2002

Volltextzugriff (PDF)

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Neurology, 2005-03, Vol.64 (6), p.992-995

2005

Volltextzugriff (PDF)

Axonal loss in normal-appearing white matter in a patient with acute MS

Neurology, 2001-10, Vol.57 (7), p.1248-1252

2001

Volltextzugriff (PDF)

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Multiple sclerosis, 2016-04, Vol.22 (5), p.668-676

2016

Volltextzugriff (PDF)

Assessing disability progression with the Multiple Sclerosis Functional Composite

Multiple sclerosis, 2009-08, Vol.15 (8), p.984-997

2009

Volltextzugriff (PDF)

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

Neurology, 1999-11, Vol.53 (8), p.1698-1698

1999

Volltextzugriff (PDF)

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Multiple sclerosis, 2002-10, Vol.8 (5), p.359-365

2002

Volltextzugriff (PDF)

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

Multiple sclerosis, 2010-05, Vol.16 (5), p.588-596

2010

Volltextzugriff (PDF)

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Neurology, 2007-04, Vol.68 (16), p.1299-1304

2007

Volltextzugriff (PDF)

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

Neurology, 2009-06, Vol.72 (23), p.1989-1993

2009

Volltextzugriff (PDF)

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

Brain (London, England : 1878), 1999-05, Vol.122 (5), p.871-882

1999

Volltextzugriff (PDF)

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

Clinical and experimental immunology, 2002-09, Vol.129 (3), p.510-518

2002

Volltextzugriff (PDF)

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Neurology, 1998-05, Vol.50 (5), p.1294-1300

1998

Volltextzugriff (PDF)

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

Neurology, 1998-05, Vol.50 (5), p.1266-1272

1998

Volltextzugriff (PDF)

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

Neurology, 2001-05, Vol.56 (10), p.1324-1330

2001

Volltextzugriff (PDF)

Management of Multiple Sclerosis

The New England journal of medicine, 1997-11, Vol.337 (22), p.1604-1611

1997

Volltextzugriff (PDF)

A longitudinal study of brain atrophy in relapsing multiple sclerosis

Neurology, 1999-07, Vol.53 (1), p.139-139

1999

Volltextzugriff (PDF)

Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules

European journal of neurology, 2020-05, Vol.27 (5), p.878-886

2020

Volltextzugriff (PDF)

Optimal reference population for the multiple sclerosis functional composite

Multiple sclerosis, 2007-08, Vol.13 (7), p.909-914

2007

Volltextzugriff (PDF)

1 – 25 von 381

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(325)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Eight-year follow-up study of brain atrophy in patients with MS

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Axonal loss in normal-appearing white matter in a patient with acute MS

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Assessing disability progression with the Multiple Sclerosis Functional Composite

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

Management of Multiple Sclerosis

A longitudinal study of brain atrophy in relapsing multiple sclerosis

Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules

Optimal reference population for the multiple sclerosis functional composite

Suchergebnisse filtern